Pyridoxal 5′-phosphate and related metabolites in hypophosphatasia: Effects of enzyme replacement therapy

• Akiyama, Tomoyuki

• Kubota, Takuo

• Ozono, Keiichi

• Michigami, Toshimi

• Kobayashi, Daisuke

• Takeyari, Shinji

• Sugiyama, Yuichiro

• Noda, Masahiro

• Harada, Daisuke

• Namba, Noriyuki

• Suzuki, Atsushi

• Utoyama, Maiko

• Kitanaka, Sachiko

• Uematsu, Mitsugu

• Mitani, Yusuke

• Matsunami, Kunihiro

• Takishima, Shigeru

• Ogawa, Erika

• Kobayashi, Katsuhiro

抄録

Objective To investigate the utility of serum pyridoxal 5′-phosphate (PLP), pyridoxal (PL), and 4-pyridoxic acid (PA) as a diagnostic marker of hypophosphatasia (HPP) and an indicator of the effect of, and patient compliance with, enzyme replacement therapy (ERT), we measured PLP, PL, and PA concentrations in serum samples from HPP patients with and without ERT. Methods Blood samples were collected from HPP patients and serum was frozen as soon as possible (mostly within one hour). PLP, PL, and PA concentrations were analyzed using high-performance liquid chromatography with fluorescence detection after pre-column derivatization by semicarbazide. We investigated which metabolites are associated with clinical phenotypes and how these metabolites change with ERT. Results Serum samples from 20 HPP patients were analyzed. The PLP-to-PL ratio and PLP concentration were elevated in all HPP patients. They correlated negatively with serum alkaline phosphatase (ALP) activity and showed higher values in more severe phenotypes (perinatal severe and infantile HPP) compared with other phenotypes. PL concentration was reduced only in perinatal severe HPP. ERT reduced the PLP-to-PL ratio to mildly reduced or low-normal levels and the PLP concentration was reduced to normal or mildly elevated levels. Urine phosphoethanolamine (PEA) concentration did not return to normal levels with ERT in most patients. Conclusions The serum PLP-to-PL ratio is a better indicator of the effect of ERT for HPP than serum PLP and urine PEA concentrations, and a PLP-to-PL ratio of <4.0 is a good indicator of the effect of, and patient compliance with, ERT.

収録刊行物

• Molecular Genetics and Metabolism

  Molecular Genetics and Metabolism 125 (1-2), 174-180, 2018-07-17

  Elsevier

キーワード

• Asfotase alfa
• Liquid chromatography
• Vitamin B6
• Diagnostic marker
• Therapeutic monitoring

詳細情報

• CRID: 1050566774879353088
• NII論文ID: 120006845807
• NII書誌ID: AA11158931
• ISSN: 10967192
• DOI: 10.1016/j.ymgme.2018.07.006
• Web Site: https://ousar.lib.okayama-u.ac.jp/58565
• Web Site: https://api.elsevier.com/content/article/PII:S1096719218301380?httpAccept=text/xml
• Web Site: https://api.elsevier.com/content/article/PII:S1096719218301380?httpAccept=text/plain
• 本文言語コード: en
• 資料種別: journal article
• データソース種別:
  • IRDB
  • Crossref
  • CiNii Articles
  • KAKEN